United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Cardinal Capital Management

Cardinal Capital Management increased its stake in United Therapeutics Co. (NASDAQ:UTHR) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,068 shares of the biotechnology company’s stock after purchasing an additional 208 shares during the quarter. Cardinal Capital Management’s holdings in United Therapeutics were worth $3,905,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Milestone Asset Management LLC lifted its stake in shares of United Therapeutics by 56.5% in the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock worth $1,014,000 after acquiring an additional 1,037 shares during the period. Janney Montgomery Scott LLC lifted its position in United Therapeutics by 9.1% in the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after purchasing an additional 789 shares during the period. JPMorgan Chase & Co. boosted its stake in United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after purchasing an additional 50,291 shares in the last quarter. Franklin Resources Inc. increased its position in shares of United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares during the period. Finally, Burney Co. increased its position in shares of United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after purchasing an additional 12,705 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on UTHR shares. LADENBURG THALM/SH SH raised their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Oppenheimer raised their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. HC Wainwright increased their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $382.08.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the completion of the sale, the executive vice president now owns 36,710 shares in the company, valued at $13,485,785.60. This represents a 17.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 121,864 shares of company stock valued at $44,516,965 over the last three months. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Trading Up 0.0 %

Shares of United Therapeutics stock opened at $370.58 on Tuesday. United Therapeutics Co. has a 1 year low of $211.61 and a 1 year high of $417.82. The stock has a 50-day moving average price of $362.00 and a 200 day moving average price of $359.42. The company has a market cap of $16.55 billion, a P/E ratio of 16.27, a P/E/G ratio of 0.92 and a beta of 0.57.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.